Clinical trials: Affective Disorder
Major Depressive Disorder
A Phase 2 Trial of OPC-64005 for Major Depressive Disorder
The objective of the trial is to compare the efficacy of OPC-64005 at 20 mg vs placebo and to assess the safety and pharmacokinetics of OPC-64005 at 10 and 20 mg in patients with major depressive disorder (MDD).The primary…
- Trial name
- NCT04244253
- Testing
- OPC-64005 20 mg , Once-daily, OPC-64005 10 mg , Once-daily
- Where
- Japan
- Volunteers
- 273 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Treatment-Resistant Depression
NRX-101 Expanded Access
The purpose of this Expanded Access Treatment Protocol is to make NRX-101 available to patients who have treatment-resistant depression and who are unable to participate in, or do not have access to, the ongoing NRX-101 clinical…
- Trial name
- NRX-101 EAP (NCT05779267)
- Testing
- NRX-101
- Where
- United States
- Sponsor
- NeuroRx, Inc.
Major Depressive Disorder, Bi-Polar Disorder
DELPhI Evaluation of Psychiatric Conditions
DELPhI acquisition and analysis software, a QuantalX Neuroscience development, which is designed to measure, analyze, and display brain electrical activity of human electroencephalogram (EEG), to transcranial magnetic stimulation…
- Conditions
- Major Depressive Disorder, Bi-Polar Disorder, ADHD, Schizophrenia
- Trial name
- NCT03842345
- Sponsor
- QuantalX Neuroscience
Bipolar Disorder
Study Evaluating Bifeprunox in Bipolar Depression
The purpose of the study is to investigate whether eight weeks of treatment with flexible doses of bifeprunox is superior to treatment with placebo in depressed patients with bipolar disorder.
- Trial name
- NCT00134459
- Testing
- Bifeprunox
- Where
- 40 sites in United States
- Volunteers
- 434 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Schizophrenia
A Bioequivalence Study of 15 mg ER OROS Paliperidone
The purpose of this study is to evaluate the bioequivalence between the Phase 3 and the to-be-marketed formulations of extended release (ER) OROS paliperidone and to evaluate the effect of food on the highest to be marketed…
- Trial name
- NCT00892489
- Testing
- ER OROS Paliperidone
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Major Depressive Disorder
Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression
The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)
- Trial name
- NCT06419608
- Testing
- BHV-7000
- Where
- 62 sites in United States
- Volunteers
- 336 people
- Sponsor
- Biohaven Therapeutics Ltd.
Depressive Disorder, Major
A Study of Lumateperone Versus Placebo in Participants With Major Depressive Disorder
The purpose of the study is to assess how well each dose of lumateperone (Dose 1 and 2) works when given alone as compared to placebo in participants with major depressive disorder (MDD; a medical condition characterized by a…
- Trial name
- CANDLE (NCT07747389)
- Testing
- Lumateperone
- Volunteers
- 585 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Major Depressive Disorder (MDD)
Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD)
The purpose of this study is to determine the efficacy and safety of 800 mg MSI-195 in reducing symptoms of depression in Major Depressive Disorder (MDD)patients with inadequate response to current antidepressant therapy.
- Trial name
- NCT01912196
- Testing
- MSI-195
- Where
- 35 sites in United States
- Volunteers
- 376 people
- Sponsor
- MSI Methylation Sciences, Inc.
Major Depressive Disorder
A Study of Aripiprazole in Patients With Major Depressive Disorder
The purpose of this 14 week, randomized, double-blind, placebo controlled study is to assess the safety and efficacy of aripiprazole to placebo as adjunctive treatment to an assigned open-label marketed antidepressant therapy…
- Trial name
- NCT00105196
- Testing
- Aripiprazole+ ADT
- Where
- 34 sites in United States
- Volunteers
- 349 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder
Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder
To compare the antidepressant efficacy and safety of subjects receiving DVS-233 SR versus subjects receiving placebo.
- Trial name
- NCT00072774
- Testing
- DVS-233 SR
- Volunteers
- 480 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Obsessive Compulsive Disorder (OCD), Bipolar Disorders
Assess the Utility of a Speech-based Machine Learning Algorithm to Predict Treatment Response to Psychiatric Interventions
This is a research study looking at whether the way people speak can help predict how well they'll respond to certain mental health treatments.
- Conditions
- Obsessive Compulsive Disorder (OCD), Bipolar Disorders, Major Depressive Disorder, Post-Traumatic Stress Disorder, PTSD
- Trial name
- NCT06823024
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Psyrin Inc.
Bipolar Disorder
Safety of SPD417 Combined With Other Psychotropic Medications in the Treatment of Bipolar I Disorder
The purpose of this study is to evaluate the safety of SPD417 when given with other psychotropic medications to treat bipolar I disorder.
- Trial name
- NCT00150605
- Testing
- Extended-release carbamazepine
- Volunteers
- 50 people
- Sponsor
- Validus Pharmaceuticals
Depressive Disorder, Major
A Safety Study in Participants With Major Depressive Disorder
The primary objective of this study is to evaluate the long-term safety and tolerability of LY2216684 administered once daily (QD) in the adjunctive treatment with a selective serotonin reuptake inhibitor (SSRI) for up to…
- Trial name
- NCT01155661
- Testing
- LY2216684 (edivoxetine), SSRI
- Where
- 48 sites in United States, Brazil and 5 more
- Volunteers
- 608 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Long-Term Administration Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder
To examine the safety and efficacy of long term administration of aripiprazole as an adjunctive therapy, co-administered with either a selective serotonin reuptake inhibitor (SSRI) or a selective-norepinephrine reuptake inhibitor…
- Trial name
- NCT00882362
- Testing
- OPC-14597 (Aripiprazole)
- Where
- 8 sites in Japan
- Volunteers
- 155 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Depression, Depressive Disorder
Digital Therapeutic for Adolescent Depressive Symptoms in Hematology, Oncology, and Weight Management
The primary aims of the proposed research are to assess the feasibility, acceptability, and preliminary evidence of efficacy of a self-guided, cognitive behavioral therapy (CBT)-based mobile app intervention (SparkRx) for the…
- Conditions
- Depression, Depressive Disorder, Depressive Symptoms, Depressive Episode
- Trial name
- NCT05351866
- Testing
- CBT-based mobile intervention for depression, Mobile control with education about depression
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Limbix Health, Inc.
Depressive Disorder
Bupropion & Cardio Birth Defect (Slone)
Bupropion is a unique drug that is used both to treat depression and as an aid in smoking cessation. In 2008, the final report from the Bupropion pregnancy registry described 24 congenital malformations among the 675 women…
- Trial name
- NCT01597661
- Testing
- Exposure to any bupropion during the first trimester, Exposure to bupropion alone during the first trimester, Referent group: no exposure to any anti-depressant or anti-smoking drug during pregnancy
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)
A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression
- Trial name
- NCT00034983
- Testing
- aprepitant, Comparator: paroxetine HCL
- Volunteers
- 900 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
A Multiple Ascending Dose Study of BCI-838 in Healthy Volunteers
This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BCI-838 and its metabolite BCI-632 in healthy male and female subjects.
- Trial name
- NCT01548703
- Testing
- BCI-838
- Where
- Netherlands
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- BrainCells Inc.
Depressive Disorder, Major
54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide
The purpose of this study is to evaluate the efficacy of intranasal esketamine 84 milligram (mg) compared with intranasal placebo in addition to comprehensive standard of care in reducing the symptoms of Major Depressive Disorder…
- Trial name
- Aspire II (NCT03097133)
- Testing
- Esketamine, Standard of Care
- Where
- 61 sites in United States, Argentina and 10 more
- Volunteers
- 230 people
- Sponsor
- Janssen Research & Development, LLC
Bipolar Depression
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on)
This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe when added to treatment with lithium or Divalproex for the treatment of patients with bipolar I depression.
- Trial name
- NCT00868452
- Testing
- lurasidone + (lithium or divalproex)
- Where
- 71 sites in United States, Czechia and 8 more
- Volunteers
- 348 people
- Sponsor
- Sumitomo Pharma America, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.